BCR::ABL1 V299L dasatinib-resistance mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-BCR-ABL1-V299L |
|---|---|
| Type | Biomarker |
| Aliases | ABL1 p.V299LBCR-ABL V299LBCR-ABL1 V299L resistance mutationBCR::ABL1 V299L — мутація резистентності до дазатинібу |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ELN-CML-2020 SRC-ELN-CML-2025 SRC-ESMO-CML-2017 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "5", "functional_impact": "dasatinib and bosutinib resistance; nilotinib and ponatinib retain activity", "gene": "ABL1", "hgvs_protein": "p.V299L", "variant_type": "missense"} |
| Measurement | MethodBCR::ABL1 kinase-domain Sanger sequencing OR targeted NGS at TKI failure Unitscategorical (positive | negative); VAF % when NGS |
| Actionability lookup | {"gene": "ABL1", "variant": "V299L"} |
| Related biomarkers | BIO-BCR-ABL1 BIO-BCR-ABL1-T315I BIO-BCR-ABL1-F317L |
Notes
Resistance to BOTH dasatinib and bosutinib via P-loop conformational change. IC50 for dasatinib elevated ~15-20x; bosutinib ~25-50x. Nilotinib retains activity (IC50 unchanged). Ponatinib and asciminib both active. Per ELN-2020 / ELN-2025: detection on dasatinib or bosutinib failure → switch to nilotinib (preferred 2G-TKI option) or ponatinib. Distinguishing V299L from F317L is clinically meaningful: F317L spares bosutinib whereas V299L does not.
Used By
Biomarker
BIO-BCR-ABL1-E255K- BCR::ABL1 E255K nilotinib-resistance mutationBIO-BCR-ABL1-F317L- BCR::ABL1 F317L resistance mutationBIO-BCR-ABL1-T315I- BCR::ABL1 T315I gatekeeper mutation